[characterized in that] <u>binding AAV-2</u> or antigen portions thereof [are bonded] to an activated chromatographic material which comprises antibodies linked thereto and directed against AAV-2, and

[then elution is carried out] <u>eluting said AAV-2 or antigen portions thereof</u> using a solution containing 0.5 to 4.5 mMgCl<sub>2</sub>.

- 2 (Amended) The method according to claim 1, wherein <u>said AAV-2</u> is [either] <u>a</u> wild-type AAV-2 or <u>a</u> recombinantly prepared AAV-2.
- 3 (Reiterated) The method according to claim 1 or 2, wherein the chromatographic material is selected from the group consisting of agarose gels, dextran gels, cellulose gel matrices and acrylamide gel matrices.
- 4. (Amended) The method according to [any one of claims 1 to 3] <u>claim 1 or 2</u>, wherein the chromatographic material carries a ligand suitable for [bonding] <u>binding</u> proteins [, particularly antibodies].
- 5. (Amended) The method according to [any one of claims 1 to 4] <u>claim 1 or 2</u>, wherein the chromatographic material is CNBr-activated sempharose® or NHS-activated sempharose®.
- 6 (Amended) The method according to [any one of claims 1 to 5] <u>claim 1 or 2</u>, wherein the [elution] solution contains 2 to 3 M MgCl<sub>2</sub>.
- 7. (Amended) The method according to [any one of claims 1 to 6] <u>claim 1 or 2</u>, wherein the sample containing the AAV-2 [and rAAV-2, respectively,] is a cell culture supernatant or cell extracts.
- 8. (Amended) The method according to [any one of claims 1 to 7] <u>claim 1 or 2</u>, wherein the antibody directed against AAV-2 is A20 (DSM ACC2194).